MedTrace Logo

Factors of ILD in Newly Diagnosed Rheumatoid Arthritis

NCT04002765 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2022-05-09

No results posted yet for this study

Summary

To determine factors associated with early RA-ILD (which may be asymptomatic). It is planned to recruit all patients with a newly diagnosed RA (symptoms since less than 3 years). In this study, all relevant demographic and clinical data will be collected. All patients will undergo lung function tests and high-resolution CT-scan of the lungs. Blood sample will be collected for measurement of (1) anti-CCP and rheumatoid factor measurement (good clinical practice) and a specific sample for the detection of the MUC5 promoter variant rs35705950.

Our aim is thus to identify determinants of RA-ILD in the following population:

* Adults aged 18 to 90 years-old
* Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria
* Onset of disease duration at least 1 year and at most 10 years prior to inclusion

Conditions

Interventions

DIAGNOSTIC_TEST

pulmonary function tests

1. Lung function tests (standard of care) 1. Dynamic and static volumes (FVC, FEV1, TPC, RV) 2. Lung diffusion capacity for CO (DLCO) 2. Chest Xrays 3. High resolution CT scanner (HRCT)

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Antoine Froidure, MD PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

  • Patrick Durez, MD PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

  • Benoît Ghaye, MD PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04002765 on ClinicalTrials.gov